NHS: Drug Shortages

Baroness Merron Excerpts

Wednesday 17th January 2024 Lords Chamber

[Lord Markham (Con)]

My noble friend is correct that this so-called off-label use of these diabetes drugs for weight-loss-type treatments is causing some of the shortages she mentions. That is exactly what we have been tackling, and we have been making sure that the only way you can get the Wegovy weight-loss drug is actually on a very tightly controlled weight management programme normally run through hospitals, and not through normal GPs, exactly to get on top of that issue.

[Baroness Merron (Lab)]

My Lords, there are reports in the media today of pharmacists having to deal with frustrated and worried customers who are faced with shortages of medicines including HRT and the drugs for ADHD, diabetes and cancer. Can the Minister indicate what action is being taken to support and gather feedback from pharmacists who are dealing with such an unsatisfactory situation? What steps are being taken to ensure that, in the future, the supply system is able to cope as soon as demand for medicines increases?

[Lord Markham (Con)]

We find that each one is a different case in point. HRT is an example: we actually saw a 50% increase in demand for it over the last year, so suddenly that is quite a dislocation for the market, and you need to gear up very quickly in terms of the supply chain issues. Strep A was the example last year that we will all be familiar with; normally, it does not come until later in the year, but suddenly there was a very early outbreak in October, which caused the demand there. You find that every single drug tends to be a different case in point. There is a range of tools that they work with; it is working with the NHS, MHRA suppliers and pharmacists, and it is case by case. As I say, sometimes it is the MHRA expediting medicines to get new supply in; sometimes it is working on alternative suppliers; sometimes it is buying internationally—that is what we did in the case of strep A—and sometimes you do have to go as far as the serious shortage protocols, finding substitutes or, in extreme cases, changing doses. There is a range of programmes on it, which by and large are managing to tackle it.